Study guide
22.2 Chronic Leukaemias & Myeloproliferative Neoplasms
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
22.2 Chronic Leukaemias & Myeloproliferative Neoplasms
Key Takeaways Explain This Topic AI
Smear (smudge) cells on the blood film are characteristic of chronic lymphocytic leukaemia; Richter transformation to diffuse large B-cell lymphoma presents with rapid nodal growth, fever and weight loss.
Chronic myeloid leukaemia carries the t(9;22) BCR-ABL1 fusion and is treated with imatinib or a later-generation tyrosine kinase inhibitor.
JAK2 V617F is present in about 95% of polycythaemia vera and about half of essential thrombocythaemia and myelofibrosis; polycythaemia vera is treated with venesection and aspirin.
Last updated: September 2026
- 2. Chronic Leukaemias & Myeloproliferative Neoplasms (MPNs)
- Chronic Myeloid Leukaemia (CML)
Cytogenetic Hallmark: Reciprocal translocation between the long arms of chromosomes 9 and 22: t(9;22)(q34;q11) . This translocates the ABL1 proto-oncogene from chromosome 9 to the breakpoint cluster region ( BCR ) on chromosome 22, generating a shortened derivative chromosome 22 known as the Philadelphia chromosome . The resultant BCR-ABL1 fusion gene encodes a constitutively active, deregulated tyrosine kinase (p210 oncoprotein) that drives autonomous granulocyte proliferation and inhibits apoptosis.
Clinical Presentation: Often asymptomatic (~40%) or presents with fatigue, weight loss, night sweats, and dragging left upper quadrant abdominal discomfort due to massive splenomegaly .
Peripheral Blood Film: Striking, dramatic leukocytosis (often >100 x 10^9/L) displaying the entire spectrum of granulocytic maturation in a smooth, continuous cascade: myeloblasts (<2%), promyelocytes, myelocytes, metamyelocytes, band forms, and mature segmented neutrophils. Absolute basophilia and eosinophilia are universal.
Discriminator: The Leukocyte Alkaline Phosphatase (LAP / NAP) score is characteristically low or zero in CML (granulocytes are functionally immature and deficient in LAP), which definitively distinguishes CML from a reactive leukaemoid reaction (severe leukocytosis secondary to sepsis or tissue necrosis, where the LAP score is markedly elevated).
Targeted Pharmacotherapy: First-line treatment with oral BCR-ABL Tyrosine Kinase Inhibitors (TKIs) : Imatinib (first-generation), or second-generation TKIs ( dasatinib, nilotinib, bosutinib ). Disease response is monitored every 3 months using quantitative RT-PCR on peripheral blood to measure BCR-ABL1 transcript levels on the International Scale (major molecular response: BCR-ABL1 <=0.1%).
Chronic Lymphocytic Leukaemia (CLL)
Epidemiology: The most prevalent leukaemia in the Western world, primarily affecting elderly adults (median age 70 years, male:female ratio 2:1).
Pathophysiology: Clonal accumulation of immunologically incompetent, mature-appearing CD5+ B lymphocytes in peripheral blood, bone marrow, spleen, and lymph nodes.
Diagnostic Criteria: Sustained absolute monoclonal B-cell lymphocytosis >=5 x 10^9/L in peripheral blood for >=3 months.
Blood Film & Immunophenotype:
Blood film shows small, uniform, mature lymphocytes with round nuclei, dense clumped ("soccer-ball") chromatin, and scant cytoplasm, alongside characteristic fragile cells damaged during slide preparation, termed "smudge cells" or "smear cells" (Gumprecht shadows) .
Flow cytometry confirms a pathognomonic co-expression profile: CD5+ (aberrant T-cell marker), CD19+, CD20+ (weak), CD23+, with weak monoclonal surface immunoglobulin .
Staging Systems (Binet Classification):
Stage A: <3 lymph node regions involved; Hb >=100 g/L, platelets >=100 x 10^9/L (median survival >10 years; managed with watchful waiting).
Stage B: >=3 lymph node regions involved; Hb >=100 g/L, platelets >=100 x 10^9/L.
Stage C: Anaemia (Hb <100 g/L) and/or thrombocytopenia (platelets <100 x 10^9/L), regardless of the number of affected lymph node areas.
Crucial Clinical Complications:
Hypogammaglobulinaemia: Occurs in up to 60% of patients due to progressive failure of normal polyclonal B-cell function, precipitating recurrent pyogenic bacterial respiratory tract infections ( Streptococcus pneumoniae , Haemophilus influenzae ). Treated with monthly prophylactic intravenous immunoglobulin (IVIG) if recurrent serious infections occur.
Autoimmune Cytopenias: 10–15% develop Warm Autoimmune Haemolytic Anaemia (AIHA) (DAT positive) or Immune Thrombocytopenia (ITP) . Exam pearl: Manage with systemic corticosteroids (oral prednisolone) , NOT cytotoxic chemotherapy!
Richter's Transformation: Catastrophic transformation of indolent CLL (in 5–10% of patients) into an aggressive, high-grade Diffuse Large B-cell Lymphoma (DLBCL) . Characterized by sudden, rapid enlargement of a localized nodal mass, severe systemic B-symptoms (drenching night sweats, fever, weight loss), and a dramatic spike in serum LDH.
Classical BCR-ABL-Negative Myeloproliferative Neoplasms (MPNs)
Driven by somatic gain-of-function driver mutations that constitutively activate the intracellular JAK-STAT (Janus kinase / signal transducer and activator of transcription) signaling pathway:
JAK2 V617F Mutation: A point mutation substituting valine for phenylalanine at codon 617 in the auto-inhibitory pseudokinase domain of JAK2 on chromosome 9p. Present in >95% of Polycythaemia Vera (PV) , and 50–60% of Essential Thrombocythaemia (ET) and Primary Myelofibrosis (PMF). The remaining ET and PMF cases carry mutations in calreticulin ( CALR ) (20–30%) or the thrombopoietin receptor ( MPL ) (5–10%).
Polycythaemia Vera (PV):
Autonomous, erythropoietin-independent proliferation of erythroid precursors, producing a true absolute expansion of red cell mass.
Laboratory Profile: Elevated haematocrit (men >0.49, women >0.48) or haemoglobin (>165 g/L in men, >160 g/L in women). Serum erythropoietin (EPO) is characteristically subnormal or undetectable (in stark contrast to secondary polycythaemia caused by chronic hypoxia, cyanotic heart disease, smoking, or EPO-secreting tumours [renal cell carcinoma, cerebellar haemangioblastoma, hepatocellular carcinoma], where serum EPO is elevated).
Clinical Manifestations: Hyperviscosity symptoms (headache, dizziness, tinnitus, blurred vision), aquagenic pruritus (severe, stinging generalized itching without rash occurring within minutes of stepping out of a warm bath or shower, mediated by basophil degranulation and histamine release), gout (from high purine turnover), and atypical venous and arterial thromboses (specifically hepatic vein thrombosis / Budd-Chiari syndrome, mesenteric thrombosis, and stroke).
Management: First-line therapy is therapeutic venesection to maintain haematocrit <0.45 (proven by the CYTO-PV trial to significantly reduce cardiovascular death and major thrombotic events), low-dose aspirin (75 mg daily), and cytoreductive therapy with hydroxycarbamide (or pegylated interferon-alfa) in high-risk patients (age >=60 years or prior thrombosis).
Primary Myelofibrosis (PMF):
Clonal proliferation of atypical megakaryocytes that release massive amounts of fibrogenic cytokines ( TGF-beta and PDGF ) into the bone marrow stroma, stimulating polyclonal fibroblasts to deposit dense collagen and reticulin fibers.
Clinical Hallmarks: Progressive bone marrow obliteration leading to a "dry tap" on bone marrow aspiration (mandating a trephine biopsy), severe extramedullary haematopoiesis (resulting in massive, symptomatic splenomegaly extending into the right iliac fossa), constitutional B-symptoms, and cachexia.
Blood Film Signature: Leucoerythroblastic blood film (simultaneous presence of immature nucleated red blood cells and immature granulocytes / myelocytes) alongside pathognomonic "tear-drop" poikilocytes (dacrocytes) , which are mechanically deformed as they squeeze out of the fibrotic bone marrow sinuses into the circulation.
Treatment: Supportive (transfusions, erythropoietin), JAK1/JAK2 inhibitor ruxolitinib (markedly shrinks splenomegaly and ameliorates debilitating constitutional symptoms), and allogeneic stem cell transplantation in young, fit patients.
3. Comparative Table: Acute vs. Chronic Leukaemias
Leukaemia Type Median Age & Demographics Pathognomonic Cytogenetics Peripheral Blood Film & Morphology Diagnostic Immunophenotype First-Line Targeted / Definitive Therapy
Acute Myeloid (AML) Elderly (65–70 yrs); rarely young t(15;17) PML-RARA in APML; t(8;21); inv(16) >=20% myeloblasts, delicate chromatin, Auer rods , MPO+ CD13+, CD33+, CD34+, CD117+ (c-kit), MPO+ 7+3 Induction (Cytarabine + Daunorubicin); ATRA + ATO for APML
Acute Lymphoblastic (ALL) Children (peak 2–5 yrs); secondary >60 yrs t(12;21) ETV6-RUNX1 (good); t(9;22) BCR-ABL1 (poor) >=20% lymphoblasts, high N:C ratio, MPO negative TdT+ , CD10+ (CALLA), CD19+, CD22+ (B-ALL); CD3+ (T-ALL) Multi-agent chemo + Intrathecal methotrexate ; TKI if Ph+
Chronic Myeloid (CML) Middle-aged adults (50–60 yrs) t(9;22)(q34;q11) (Philadelphia chr; BCR-ABL1) Striking leukocytosis (>100 x 10^9/L), entire granulocytic cascade, basophilia, low LAP Neutrophil lineage markers; negative for acute blast markers Tyrosine Kinase Inhibitors (Imatinib, Dasatinib, Nilotinib)
Chronic Lymphocytic (CLL) Elderly adults (>65 yrs); M > F del(17p) TP53 (poor); del(13q) (good prognosis) Small, mature-looking lymphocytes with clumped chromatin, smudge cells CD5+ , CD19+, CD20+ (weak), CD23+ , weak sIg Watchful waiting (Binet A); Targeted agents (Venetoclax, BTK inhibitors)